EuroTransBio project granted !
We are pleased to announce the approval of our EuroTransBio-project named:
3d HEARSTCREEN, A New Drug Discovery platform combining in silico screening 3D-visualization and human heart cell validation
The project is a collaboration between Virtual Proteins BV, Eindhoven, The Netherlands, Lead Pharma Holding BV, Den Bosch, The Netherlands and Silicos NV, Diepenbeeke, Belgium. The EuroTransbio funding enhances the set up of a new drug discovery platform that integrates the proprietary technologies of the individual companies. The effectiveness of this platform in reducing lead discovery time and costs will be demonstrated on a heart failure target. The project has a budget of 2.6 million € and a duration of 2.8 years. The platform is available for commercial use on request.
The progress of the project will be published and frequently updated on:
Official 3D heartscreen website
For more information about the participating companies and their emerging technologies,please check out their company websites:>